Brought to you by 
Novartis licenses rights to Proteus' IP to develop drugs
21 Apr 2021
Executive Summary
Novartis has licensed exclusive global rights to develop and market organ transplant drugs that incorporate Proteus Biomedical's (micro-electromechanical systems for congestive heart failure) sensor-based technologies.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis licenses rights to Proteus' IP to develop drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice